Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Elmfeldt, D ^a   George, M ^b   Hubner R ^b   Olofsson, B ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Takeda Pharma GmbH   (Germany)

Author keywords

Candesartan cilexetil; Dose response; Hypertension; Meta analysis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; NEW DRUG; PRODRUG;

ADULT; AGE; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; EUROPE; FEMALE; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PATIENT; RANDOMIZED CONTROLLED TRIAL; SITTING; STANDING; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030661710     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Noda M et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide All antagonist. Biochem Pharmacol 1993; 46: 311-318.
2. 1 receptor. Eur J Pharmacol 1997; 319: 137-146.
3. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S27-S28.
4. Hübner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S19-S25.
5. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S63-S64.
6. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997; 11 (Suppl 2): S61-S62.
7. Philipp T, Letzel H, Arens HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S67-S68.
8. Farsang CH et al. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10 (4 Pt 2): 80A.
9. O'Brien E, Mee F, Atkins N. An accurate automated device for home blood pressure measurement at last! The Omron HEM-705CP. J Hvpertens 1994; 12: 1317-1318.
10. Weber F et al. Indirect and direct simultaneous, comparative blood pressure measurements with the new 'Bosotron 2' device. Kidney Blood Press Res 1997; (in press).
11. Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46: 63-77.
12. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994. J Vasc Med Biol 1993;4:265-71.
13. Gradman AH et al. A randomised, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
14. Oddou-Stock P et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension. Am J Hypertens 1997; 10: 84A (abstract).
15. Neaton JD et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713-724.
16. Materson BJ et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
17. Oparil S et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 707-810.
18. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-Ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic Acid (CV-11974), and its prodrug, (±)-1-(Cyclohexyloxycarbonyloxy)-ethyl 2-Ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
19. Brunner HR, Gavras H, Laragh JH, Keenan R. Angiotensin II blockade in man by Sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 2; 1045-1048.